Pereira Higor Sette, Tagliaferri Thaysa Leite, Mendes Tiago Antônio de Oliveira
Laboratory of Synthetic Biology and Modelling of Biological Systems, Department of Biochemistry and Molecular Biology, Universidade Federal de Viçosa, Viçosa, Brazil.
Front Microbiol. 2021 Feb 19;12:606360. doi: 10.3389/fmicb.2021.606360. eCollection 2021.
In the post-genomic era, molecular treatments and diagnostics have been envisioned as powerful techniques to tackle the antimicrobial resistance (AMR) crisis. Among the molecular approaches, aptamers and CRISPR-Cas have gained support due to their practicality, sensibility, and flexibility to interact with a variety of extra- and intracellular targets. Those characteristics enabled the development of quick and onsite diagnostic tools as well as alternative treatments for pan-resistant bacterial infections. Even with such potential, more studies are necessary to pave the way for their successful use against AMR. In this review, we highlight those two robust techniques and encourage researchers to refine them toward AMR. Also, we describe how aptamers and CRISPR-Cas can work together with the current diagnostic and treatment toolbox.
在后基因组时代,分子治疗和诊断被视为应对抗菌药物耐药性(AMR)危机的有力技术。在分子方法中,适体和CRISPR-Cas因其实用性、敏感性以及与多种细胞外和细胞内靶点相互作用的灵活性而获得了支持。这些特性推动了快速现场诊断工具的开发以及针对泛耐药细菌感染的替代治疗方法的发展。即便有这样的潜力,仍需要更多研究为它们成功对抗AMR铺平道路。在本综述中,我们重点介绍这两种强大的技术,并鼓励研究人员针对AMR对其进行改进。此外,我们还描述了适体和CRISPR-Cas如何与当前的诊断和治疗工具箱协同工作。